Shingles Vaccine May Reduce Cardiovascular Disease Risk by 9%
Recent research shows that the shingles vaccine may help reduce the risk of cardiovascular disease. A boy and the sea · E+/Getty A recent study found that the recombinant shingles vaccine (Shingrix) was associated with a 9% lower cardiovascular disease burden compared with the older live vaccine. Researchers observed lower burdens of coronary heart disease, heart failure, ischemic stroke in men,…
A recent study suggests that the recombinant shingles vaccine, known as Shingrix, may lower the risk of cardiovascular disease by 9%. Researchers found that individuals who received Shingrix had significantly lower burdens of coronary heart disease, heart failure, ischemic stroke in men, and atrial fibrillation compared to those who received the older live vaccine, Zostavax.
The study, published in Nature Medicine, compared people who had received Shingrix to those who were unvaccinated, as well as those who had received Zostavax before its discontinuation in 2020. While the findings are promising, researchers caution that the study is observational, meaning it cannot definitively prove cause and effect.
More research is needed to understand the exact mechanisms behind the association between shingles vaccination and reduced cardiovascular disease risk. Experts suggest that the vaccine's anti-inflammatory properties, triggered by its recombinant nature, may help explain the observed benefits.
Written by urgent.news from Healthline News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
